Hematology, Transfusion and Cell Therapy最新文献

{"title":"Survival of trauma patients requiring massive transfusion protocol activation: A retrospective cohort study at a tertiary hospital in Malaysia","authors":"Mohd Redzuan Abdullah,&nbsp;Thaenujah Nair Ramachandran,&nbsp;Aidil Noor Adnan,&nbsp;Azian Md Yacob,&nbsp;Siti Fatimah Mohamed Kamaruzzaman,&nbsp;Ahmad Zakimi Abdullah,&nbsp;Nurul Aiman Addenan,&nbsp;Maryam Sumaiya Ahmad Termizi,&nbsp;Joan Gan Cheau Yan,&nbsp;Seniyah Md Sikin,&nbsp;Low Wen Ying,&nbsp;Azarina Zakaria,&nbsp;Wagner Loo Cheng Poh,&nbsp;Zulkifli Hassan,&nbsp;Alex Lim Tat Leong,&nbsp;Siti Aisah Hassan","doi":"10.1016/j.htct.2026.106489","DOIUrl":"10.1016/j.htct.2026.106489","url":null,"abstract":"<div><h3>Background</h3><div>Trauma is one of the main causes of morbidity and mortality worldwide. Understanding the factors affecting the survivability of trauma patients is crucial, especially those requiring the activation of the massive transfusion protocol. This study aimed to determine survival outcomes and identify factors associated with mortality among trauma patients requiring massive transfusion activation.</div></div><div><h3>Materials and methods</h3><div>This was a retrospective cohort study of 71 trauma patients who required activation of the massive transfusion protocol. The trauma patients were divided into Survivor (n = 41) and Non-survivor groups (n = 30). The activation criteria for massive transfusions were an assessment of blood consumption score ≥2.</div></div><div><h3>Results</h3><div>The hospital mortality rate for trauma patients who required activation of the massive transfusion protocol was 42.3%. Most of the patients were male (90.1%), of Malay ethnicity (49.3%), and had blood group O (40.8%). The commonest cause of trauma was road traffic accidents (84.5%). Patients with severe Glasgow Coma Scores had approximately 4.2 times higher odds of mortality compared with those with non-severe Glasgow Coma Scores (p-value = 0.014). Haemoglobin level was independently associated with outcome, with lower haemoglobin levels observed among non-survivors (adjusted odds ratio: 1.38; 95% CI: 1.03–1.85; p-value = 0.030).</div></div><div><h3>Conclusions</h3><div>The survivability of trauma patients who need massive transfusion protocol activation was associated with Glasgow Coma Score and haemoglobin level on arrival. It is crucial to determine factors that affect the survivability of trauma patients for the early identification of those at risk and to initiate prompt management and resuscitation in the future.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106489"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet counts, but not neutrophil counts, are associated with non-bleeding-related mortality in patients with hematological malignancies and post-chemotherapy febrile neutropenia","authors":"Gabriela Romantini Salioni,&nbsp;Carla Roberta Peachazepi Moraes,&nbsp;Leticia Queiroz da Silva,&nbsp;Edwin Mayr,&nbsp;Bruno Kosa Lino Duarte,&nbsp;Erich V De Paula","doi":"10.1016/j.htct.2026.106498","DOIUrl":"10.1016/j.htct.2026.106498","url":null,"abstract":"<div><h3>Introduction</h3><div>Neutrophils and platelets are key elements of the host immune response to sepsis, participating in both pathogen clearance and in sepsis-related tissue damage. Although it is widely recognized that patients with hematological malignancies and chemotherapy-induced febrile neutropenia are at increased risk of severe sepsis complications, the prognostic impact of neutrophil and platelet counts on sepsis-related outcomes remains controversial, with conflicting results regarding the magnitude of neutropenia. Moreover, to our knowledge, no studies have addressed the association of thrombocytopenia with outcomes in febrile neutropenia in patients with hematological malignancies. This study investigated the association of neutropenia and thrombocytopenia in a consecutive cohort of 113 patients with underlying hematological malignancies who were admitted to an academic tertiary hospital with chemotherapy-induced neutropenia.</div></div><div><h3>Methods</h3><div>Neutrophil and platelet counts were obtained at fever onset and 24, 48 and 72 hours thereafter.</div></div><div><h3>Results</h3><div>Neutrophil counts at the time of febrile neutropenia were not associated with sepsis-related mortality or other negative outcomes. However, a lower platelet count at fever onset was associated with non-bleeding sepsis-related mortality and the need of organ support. Moreover, the trajectories of both neutrophil and platelet counts in the first 72 hours after the onset of febrile neutropenia were also associated with negative outcomes.</div></div><div><h3>Conclusion</h3><div>These results highlight the heterogeneous role of platelets in the immune response and pave the way for studies exploring to what extent severe thrombocytopenia modulates the molecular and cellular mechanisms of post-febrile neutropenia sepsis in these patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106498"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO)","authors":"Afonso C. Vigorito,&nbsp;Carmino A. de Souza,&nbsp;Nelson Hamerschlak,&nbsp;Vaneuza A.M. Funke,&nbsp;Maria Claudia R. Moreira,&nbsp;Adriana Seber,&nbsp;Renato Luiz Guerino Cunha,&nbsp;Wanderley Bernardo,&nbsp;Fernando B. Duarte","doi":"10.1016/j.htct.2026.106494","DOIUrl":"10.1016/j.htct.2026.106494","url":null,"abstract":"<div><div>Graft-versus-host disease, involving from 20%–80% of patients, is one of the main complications of allogeneic hematopoietic cell transplantation contributing significantly to mortality and morbidity. The methodological basis of these graft-versus-host disease prophylaxis guidelines for allogeneic hematopoietic cell transplantation, developed by the Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH) and the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), is a review which applied the GRADE process to eleven PICO (population, intervention, comparator, and outcome) questions. These questions address graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation across various settings, including myeloablative and non-myeloablative/reduced-intensity conditioning. The scope encompasses related matched, unrelated matched or mismatched, and haploidentical donors, utilizing both bone marrow and peripheral blood as stem-cell sources. The combination of a calcineurin inhibitor (e.g., cyclosporine or tacrolimus) plus methotrexate or mycophenolate mofetil (MMF) has been the standard graft-versus-host disease prophylaxis regimen for allogeneic hematopoietic cell transplantation. The excellent results of post-transplant cyclophosphamide in haploidentical related donor hematopoietic cell transplantation have led to broader use in human leukocyte antigen-(mis)matched related and unrelated donor grafts. Sirolimus, low-dose antithymocyte globulin (4–6 mg/kg) and more recently abatacept are other drugs used. Hence, this review is meant to be a useful reference tool for clinicians who are dealing with this complex complication.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106494"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent mortality risk of plasma transfusion in critically ill patients","authors":"Min Zhang,&nbsp;Hongjun Gao,&nbsp;Chushu Liao,&nbsp;Fen Yuan,&nbsp;Zhen Huang,&nbsp;Xisha Huan,&nbsp;Shan Feng,&nbsp;Fangfang Chen,&nbsp;Ping Lei","doi":"10.1016/j.htct.2026.106491","DOIUrl":"10.1016/j.htct.2026.106491","url":null,"abstract":"<div><h3>Objectives</h3><div>Plasma transfusion is commonly used in intensive care units, often for non-bleeding indications despite limited evidence. This study aimed to evaluate the association between plasma transfusions and in-hospital mortality among critically ill patients.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using data from 282 adult intensive care unit patients who received transfusion therapy between January and December 2020. Patients were grouped by their exposure to plasma transfusion and further by the transfusion volume. First, multivariable Cox regression coupled with propensity score matching was used to control for baseline confounders and quantify the independent association of plasma transfusion with in-hospital mortality. Subsequently, Cox models and Kaplan-Meier survival curves were employed to elucidate the dose-response relationship between transfusion volume and mortality risk, with additional subgroup analyses.</div></div><div><h3>Results</h3><div>In the unadjusted analysis, plasma transfusion was significantly associated with increased in-hospital mortality (Hazard ratio = 4.199; 95% confidence interval: 2.53–6.97; p-value &lt;0.001). This association persisted after propensity score matching adjusted for key confounders (Hazard ratio = 3.271; 95% confidence interval: 1.30–8.21; p-value = 0.012). Kaplan-Meier survival analysis demonstrated significantly lower survival probabilities in the transfusion group (log-rank p-value &lt;0.05). Furthermore, a dose-dependent relationship was revealed: mortality risk increased at higher volumes, reaching statistical significance at &gt;800 mL (Hazard ratio = 4.09; 95% confidence interval: 1.19–14.04; p-value = 0.025). Subgroup analysis indicated that the elevated risk was particularly pronounced among patients who concurrently received red blood cell transfusions.</div></div><div><h3>Conclusion</h3><div>Plasma transfusion is independently and dose-dependently associated with increased mortality in critically ill patients, particularly when used without clear indications. These findings support a restrictive, evidence-based approach, emphasizing correction of underlying coagulopathy over prophylactic transfusion. Strict adherence to guidelines and an individualized risk-benefit assessment are essential to improve patient safety.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106491"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MPL mutations are over-represented in patients with dual driver-mutated myeloproliferative neoplasms: an Irish cohort study","authors":"Laura Kearney,&nbsp;Claire Andrews,&nbsp;Rachel Brodie,&nbsp;Ezzat Elhassadi,&nbsp;Helen Enright,&nbsp;Kamal Fadalla,&nbsp;Michael Fay,&nbsp;Catherine Flynn,&nbsp;Anne Fortune,&nbsp;Andrew Hodgson,&nbsp;Senthil Kumar,&nbsp;Kanthi Perera,&nbsp;Jeremy Sargent,&nbsp;Liam Smyth,&nbsp;Stephen E. Langabeer","doi":"10.1016/j.htct.2026.106495","DOIUrl":"10.1016/j.htct.2026.106495","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106495"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of intravenous ferric derisomaltose in Brazilian patients with iron deficiency anemia","authors":"Lauro Augusto Caetano Leite,&nbsp;Gisele dos Santos Barros,&nbsp;Thomas Azevedo do Carmo,&nbsp;Rodolfo Delfini Cançado","doi":"10.1016/j.htct.2026.106501","DOIUrl":"10.1016/j.htct.2026.106501","url":null,"abstract":"<div><h3>Background</h3><div>Iron deficiency anemia remains a major global health concern, especially among women, children, and people with chronic illnesses. Oral iron therapy is the standard treatment, but it is often limited by gastrointestinal side effects or poor absorption. Intravenous ferric derisomaltose is a newer formulation that allows high-dose, rapid iron replenishment with a favorable safety profile. This study aimed to assess the effectiveness and safety of intravenous ferric derisomaltose in patients with iron deficiency anemia who could not tolerate or did not respond to oral iron.</div></div><div><h3>Methods</h3><div>This was a prospective, open-label, single-center trial conducted in São Paulo, Brazil. Adult patients (≥18 years) with iron deficiency anemia received 1 or 2 infusions of intravenous ferric derisomaltose (up to 1000 mg per infusion). Hematologic and iron parameters were measured at baseline, Week 4, and Week 8. Safety outcomes included adverse events and serum phosphate levels.</div></div><div><h3>Results</h3><div>Thirty patients were treated with 25 requiring a second infusion. Significant increases in hemoglobin, serum ferritin, transferrin saturation, and reticulocyte hemoglobin content were seen at both time points. By Week 8, 81% achieved a hemoglobin increase ≥2 <em>g</em>/dL, and 54% achieved an increase of ≥3 <em>g</em>/dL. Four (8%) mild adverse events occurred and three patients (10%) experienced transient, asymptomatic hypophosphatemia, which resolved without intervention.</div></div><div><h3>Conclusion</h3><div>This study contributes to the growing evidence supporting the use of intravenous ferric derisomaltose as a safe and effective alternative for distinct populations with iron deficiency anemia. In this real-world clinical setting, the treatment is effective for treating patients with iron deficiency, providing rapid hematologic recovery with a favorable safety profile.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106501"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13393526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of survival among children with Burkitt lymphoma treated at a single center in Tanzania: a retrospective cohort study","authors":"Aika A. Shoo,&nbsp;Advera I. Ngazia,&nbsp;Nahya S. Masoud,&nbsp;Shakilu Jumanne,&nbsp;James J. Yahaya","doi":"10.1016/j.htct.2026.106496","DOIUrl":"10.1016/j.htct.2026.106496","url":null,"abstract":"<div><h3>Background</h3><div>Despite improvements in the management of patients with Burkitt lymphoma, the survival rate in low- and middle-income countries remains poor. This study aimed to determine the predictors of 18-month overall survival among children with Burkitt lymphoma.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted at the Pediatric Oncology unit of Muhimbili National Hospital in Dar-es-salaam, Tanzania. The study included a cohort of 123 children who were diagnosed with Burkitt lymphoma from January 2012 to December 2017. Predictors of mortality were assessed using Cox regression analysis. A two-tailed p-value &lt;0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>The median age of the patients was seven years and the majority 61.8% (76/123) were males. Abdominal presentation was the most common tumor site in 39% (48/123). The 18-month overall survival rate was 54.0%. Key predictors of mortality included human immunodeficiency virus (HIV) infection (adjusted Hazard ratio [aHR] = 5.12; 95% CI: 1.39–19.0; p &lt; 0.01) and elevated lactate dehydrogenase levels (&gt;500 U/L; aHR = 2.50; 95% CI: 1.14–14.71; p = 0.03).</div></div><div><h3>Conclusion</h3><div>Most patients presented with abdominal Burkitt lymphoma. Despite the tumor's high chemosensitivity, treatment response in this cohort was marginal, characterized by moderate overall survival and low event-free survival. HIV infection and elevated lactate dehydrogenase levels were significant predictors of mortality. Improving outcomes will require optimized early diagnosis, HIV screening, and rigorous patient follow-up.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106496"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroprevalence of transfusion-transmitted infections: A five-year multicentric study of 87,878 blood donors in the Mumbai region, India","authors":"Yoganand Vishwasrao Patil,&nbsp;Mrunal Vijay Kesari,&nbsp;Kalaivanan V,&nbsp;Shilpa Jain,&nbsp;Dina Abhani,&nbsp;Sagarika Khobaragade","doi":"10.1016/j.htct.2026.106492","DOIUrl":"10.1016/j.htct.2026.106492","url":null,"abstract":"<div><h3>Introduction</h3><div>Blood transfusion is a critical component of modern medicine, yet the risk of transfusion-transmitted infections remains a significant challenge. Despite stringent screening protocols, infections such as hepatitis B, hepatitis C, human immunodeficiency virus, and syphilis continue to pose risks. Understanding the seroprevalence of transfusion-transmitted infections in blood donors is essential for improving transfusion safety and shaping public health strategies. The objective of this study is to evaluate transfusion-transmitted infection seroprevalence, analyze trends, and assess seropositivity by age, donation type, and co-infections over five years.</div></div><div><h3>Materials and methods</h3><div>A five-year cross-sectional study (2020–2024) was conducted at three blood centers: Jagjivan Ram Hospital Blood Bank (Mumbai), Bloodline Charitable Blood Bank (Thane), and Sadguru Charitable Blood Centre (Navi Mumbai). The study assessed the prevalence of transfusion-transmitted infections by screening 87,878 donor samples for human immunodeficiency virus, hepatitis B, hepatitis C, syphilis, and malaria using standardized diagnostic methods. Donor demographics, infection patterns, and regional variations were analyzed statistically.</div></div><div><h3>Results</h3><div>The overall seroprevalence of transfusion-transmitted infections was 0.78%, with Hepatitis B being the most common infection (0.48%), followed by syphilis (0.144%), human immunodeficiency virus (0.078%), and hepatitis C (0.075%). No malaria cases were detected. Seropositivity was highest among younger donors (18–30 years) and predominant among males (97%). Mumbai recorded the highest seroprevalence, followed by Navi Mumbai and Thane. Co-infections were rare, with human immunodeficiency virus with syphilis being the most frequently observed combination.</div></div><div><h3>Conclusion</h3><div>This study identifies Hepatitis B as the most common transfusion-transmitted infection, followed by syphilis, human immunodeficiency virus, and hepatitis C. This study emphasizes the need for better detection strategies, specifically the use of enzyme-linked immunosorbent assay, electrochemiluminescence Immunoassay, and individual donor nucleic acid testing to improve blood safety. Transfusion-transmitted infection screening plays a vital role as a quality indicator for blood banks, driving method evaluation and improvements. Mumbai’s structured referral system ensures seropositive donors receive counseling and treatment, reinforcing blood safety protocols.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106492"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of nutritional risk index and body mass index in predicting survival outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study","authors":"Bruna Silvestre Françoso ,&nbsp;Isabela Laurêncio Schiavoni ,&nbsp;Thauany Nantes Guirao ,&nbsp;Barbara David dos Santos ,&nbsp;Thalita Cristina de Mello Costa ,&nbsp;Anderson Marliere Navarro ,&nbsp;Fabiola Traina ,&nbsp;Juliana Maria Faccioli Sicchieri","doi":"10.1016/j.htct.2026.106254","DOIUrl":"10.1016/j.htct.2026.106254","url":null,"abstract":"<div><h3>Introduction</h3><div>Allogeneic hematopoietic stem cell transplantation is a viable therapeutic option for several serious diseases however it is a high-risk procedure because it involves high-toxicity protocols with many adverse effects. Existing factors, such as the underlying disease and nutritional status, may influence the outcome. The objective of this study was to evaluate the Nutritional Risk Index as a prognostic tool by correlating it with body mass index, nutritional status, and clinical outcomes in patients undergoing hematopoietic stem cell transplantation.</div></div><div><h3>Methods</h3><div>This single center retrospective study was conducted collected sociodemographic, anthropometric, biochemical, and clinical data before conditioning and 30 days post-transplantation. Statistical analyses were performed using the Mann-Whitney test and Spearman's correlation. Overall survival was estimated using the Kaplan-Meier method, with comparisons conducted via the Gehan-Breslow-Wilcoxon test. A Cox Proportional Hazards regression analysis was employed to identify factors associated with mortality; variables demonstrating a p-value ≤0.20 in the univariate analysis were included in the multivariate model. For all analyses, statistical significance was defined as a p-value &lt;0.05.</div></div><div><h3>Results</h3><div>Seventy-seven participants were included, with an average age of 41 years. According to the nutritional risk index, the entire sample was classified as having severe nutritional risk. The body mass index showed that 6.4 % were malnourished, 19.4 % were obese, and 12.9 % had hypoalbuminemia. The estimated survival curve identified a significant difference for patients aged &lt;45 years with survival being significantly longer (p-value = 0.01). Higher albumin levels (≥3.5) after transplantation were associated with longer survival (p-value = 0.04). Sex, body mass index, albumin level before conditioning, and graft-versus-host disease showed no significant differences in terms of survival. Albumin levels ≥3.5 g/dL after transplantation were marginally associated with a lower mortality risk and malignant disease showed a trend toward increased mortality.</div></div><div><h3>Conclusion</h3><div>These findings underscore the clinical utility of prognostic indices, such as the Nutritional Risk Index and albumin levels, during the pre-transplant period, emphasizing the necessity for early nutritional interventions in hematopoietic stem cell transplantation patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106254"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146170381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells","authors":"Lena Avinery ,&nbsp;Danielle Regev ,&nbsp;Hazem Khamaisi ,&nbsp;Jacob Gopas ,&nbsp;Jamal Mahajna","doi":"10.1016/j.htct.2025.106240","DOIUrl":"10.1016/j.htct.2025.106240","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic myeloid leukemia is an adult leukemia, constituting 15 % of all leukemia diagnoses. The fundamental driver of disease pathogenesis is the Bcr/Abl fusion protein, characterized by dysregulated tyrosine kinase activity. Abl kinase inhibitors have become the mainstay of treatment, however, patients often develop resistance due to genetic alterations, particularly affecting the Bcr/Abl oncoprotein. The tumor microenvironment is also associated with acquired resistance to Abl kinase inhibitors in chronic myeloid leukemia.</div></div><div><h3>Methods</h3><div>The influence of hypoxic conditions on the development of chemoresistance to certain Abl kinase inhibitors was investigated in chronic myeloid leukemia.</div></div><div><h3>Results</h3><div>This study showed that hypoxia increased resistance to crizotinib, while imatinib resistance was modest. Both drugs effectively inhibited Bcr/Abl activity. Interestingly, the JAK1/2 inhibitor ruxolitinib further enhanced chemoresistance to crizotinib under hypoxic conditions. Hypoxia-inducible factor 1α (HIF1α) overexpression in JAK2 knockdown experiments confirmed their cooperative role in mediating crizotinib resistance. In addition, 2-methoxyestradiol, a non-estrogenic estradiol metabolite, restored crizotinib sensitivity under hypoxia and the combination of 2-methoxyestradiol with a JAK2 inhibitor showed promising results in overcoming crizotinib resistance.</div></div><div><h3>Conclusion</h3><div>In summary, this study shows the critical role of selective targeting of components of the HIF1α signaling pathway for the complete eradication of chronic myeloid leukemia cells.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106240"},"PeriodicalIF":1.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}